Hematopoietic stem progenitor cells with malignancy-related gene mutations in patients with acquired aplastic anemia are characterized by the increased expression of CXCR4.
Article in EJHaem, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
2 citing papers in PubMed, 3 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
20 authors at 6 institutions in 3 countries.
Takamasa KatagiriDepartment of Clinical Laboratory Science Graduate School of Medical Science Institute of Medical Pharmaceutical and Health Sciences Kanazawa University Kanazawa Ishikawa Japan.ORCID https://orcid.org/0000-0002-9568-8682
Jorge Luis EspinozaDepartment of Occupational Therapy Graduate School of Medical Science Institute of Medical Pharmaceutical and Health Sciences Kanazawa University Kanazawa Ishikawa Japan.
Mizuho UemoriDepartment of Clinical Laboratory Science Graduate School of Medical Science Institute of Medical Pharmaceutical and Health Sciences Kanazawa University Kanazawa Ishikawa Japan.
Honoka IkedaDepartment of Clinical Laboratory Science Graduate School of Medical Science Institute of Medical Pharmaceutical and Health Sciences Kanazawa University Kanazawa Ishikawa Japan.
Kohei HosokawaDepartment of Hematology Faculty of Medicine Institute of Medical Pharmaceutical and Health Sciences Kanazawa University Kanazawa Ishikawa Japan.
Ken IshiyamaDepartment of Hematology Faculty of Medicine Institute of Medical Pharmaceutical and Health Sciences Kanazawa University Kanazawa Ishikawa Japan.ORCID https://orcid.org/0000-0002-6189-0620
Takeshi YoroidakaDepartment of Hematology Faculty of Medicine Institute of Medical Pharmaceutical and Health Sciences Kanazawa University Kanazawa Ishikawa Japan.
Tatsuya ImiDepartment of Hematology Faculty of Medicine Institute of Medical Pharmaceutical and Health Sciences Kanazawa University Kanazawa Ishikawa Japan.
Hiroyuki TakamatsuDepartment of Hematology Faculty of Medicine Institute of Medical Pharmaceutical and Health Sciences Kanazawa University Kanazawa Ishikawa Japan.ORCID https://orcid.org/0000-0001-9515-0017
Tatsuhiko OzawaDepartment of Immunology Faculty of Medicine Academic Assembly University of Toyama Toyama City Toyama Japan.
Hiroyuki KishiDepartment of Immunology Faculty of Medicine Academic Assembly University of Toyama Toyama City Toyama Japan.
Yasuhiko YamamotoDepartment of Biochemistry and Molecular Vascular Biology Kanazawa University Graduate School of Medical Sciences Kanazawa Ishikawa Japan.
Yoshinori YoshidaCenter for iPS Cell Research and Application Kyoto University Sakyo-ku Kyoto Japan.
Kazuhisa ChonabayashiCenter for iPS Cell Research and Application Kyoto University Sakyo-ku Kyoto Japan.
Katsuto TakenakaDepartment of Hematology Clinical Immunology and Infectious Diseases Ehime University Graduate School of Medicine Toon Ehime Japan.
Koichi AkashiDepartment of Medicine and Biosystemic Science Kyushu University Graduate School of Medical Sciences Fukuoka City Fukuoka Japan.
Yasuhito NannyaDivision of Hematopoietic Disease Control Institute of Medical Science University of Tokyo Minato-ku Tokyo Japan.
Seishi OgawaDepartment of Pathology and Tumor Biology Kyoto University Yoshida-Konoe-cho Sakyo-ku Kyoto Japan.
Shinji NakaoDepartment of Hematology Faculty of Medicine Institute of Medical Pharmaceutical and Health Sciences Kanazawa University Kanazawa Ishikawa Japan.
Kanazawa University · JPKyoto University · JPUniversity of Toyama · JPEhime University · JPKyushu University · JPSohag University · EG
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
The phenotypic changes in hematopoietic stem progenitor cells (HSPCs) with somatic mutations of malignancy-related genes in patients with acquired aplastic anemia (AA) are poorly understood. As our initial study showed increased CXCR4 expression on HLA allele-lacking (HLA[-]) HSPCs that solely support hematopoiesis in comparison to redundant HLA(+) HSPCs in AA patients, we screened the HSPCs of patients with various types of bone marrow (BM) failure to investigate their CXCR4 expression. In comparison to healthy individuals (
Indexed as
acquire aplastic anemiaclonal hematopoiesisCXCR4hematopoietic stem progenitor cell (HSPC)HLA class I allele‐lacking cell
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Hematopoietic stem progenitor cells with malignancy-related gene mutations in patients with acquired aplastic anemia are characterized by the increased expression of CXCR4. · full record | OpenQuestion